Polyglutamine diseases: protein cleavage and aggregation

被引:89
|
作者
Zoghbi, HY [1 ]
Orr, HT
机构
[1] Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA
[2] Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA
关键词
D O I
10.1016/S0959-4388(99)00013-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Neuronal aggregates of the disease-causing protein, often in the nucleus of affected cells, are a pathological hallmark of the neurodegenerative diseases known as polyglutamine disorders, it was suggested that these nuclear aggregates are the cause of these disorders. However, recent evidence suggests that the aggregates, in fact, are not the pathogenic basis and, instead, may play a role in sequestration of the pathogenic protein.
引用
收藏
页码:566 / 570
页数:5
相关论文
共 50 条
  • [1] Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases
    Takeuchi, Toshihide
    Nagai, Yoshitaka
    BRAIN SCIENCES, 2017, 7 (10):
  • [2] Therapeutic approaches to polyglutamine diseases: Combating protein misfolding and aggregation
    Herbst, Martin
    Wanker, Erich E.
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (20) : 2543 - 2555
  • [3] Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process
    Escalona-Rayo, Oscar
    Fuentes-Vazquez, Paulina
    Leyva-Gomez, Gerardo
    Cisneros, Bulmaro
    Villalobos, Rafael
    Magana, Jonathan J.
    Quintanar-Guerrero, David
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2017, 43 (06) : 871 - 888
  • [4] Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases
    Minakawa, Eiko N.
    Nagai, Yoshitaka
    FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [5] POLYGLUTAMINE AGGREGATION IN HUNTINGTON AND RELATED DISEASES
    Polling, Saskia
    Hill, Andrew F.
    Hatters, Danny M.
    TANDEM REPEAT POLYMORPHISMS: GENETIC PLASTICITY, NEURAL DIVERSITY AND DISEASE, 2012, 769 : 125 - 140
  • [6] Inhibition of Protein Misfolding/Aggregation Using Polyglutamine Binding Peptide QBP1 as a Therapy for the Polyglutamine Diseases
    H. Akiko Popiel
    Toshihide Takeuchi
    James R. Burke
    Warren J. Strittmatter
    Tatsushi Toda
    Keiji Wada
    Yoshitaka Nagai
    Neurotherapeutics, 2013, 10 : 440 - 446
  • [7] Inhibition of Protein Misfolding/Aggregation Using Polyglutamine Binding Peptide QBP1 as a Therapy for the Polyglutamine Diseases
    Popiel, H. Akiko
    Takeuchi, Toshihide
    Burke, James R.
    Strittmatter, Warren J.
    Toda, Tatsushi
    Wada, Keiji
    Nagai, Yoshitaka
    NEUROTHERAPEUTICS, 2013, 10 (03) : 440 - 446
  • [8] Molecular origin of polyglutamine aggregation in neurodegenerative diseases
    Khare, SD
    Ding, F
    Gwanmesia, KN
    Dokholyan, NV
    PLOS COMPUTATIONAL BIOLOGY, 2005, 1 (03) : 230 - 235
  • [9] Aggregation formation in the polyglutamine diseases: Protection at a cost?
    Todd, Tiffany W.
    Lim, Janghoo
    MOLECULES AND CELLS, 2013, 36 (03) : 185 - 194
  • [10] DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases
    Nan Zhang
    Brittani Bewick
    Jason Schultz
    Anjana Tiwari
    Robert Krencik
    Aijun Zhang
    Kaho Adachi
    Guangbin Xia
    Kyuson Yun
    Partha Sarkar
    Tetsuo Ashizawa
    Neurotherapeutics, 2021, 18 : 1710 - 1728